Published by Ministry of Health, Labour and Welfare

 ${\mathfrak S}$

Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions Quetiapine fumarate

March 19, 2019

Non-proprietary name

Quetiapine fumarate

Safety measure

Precautions should be revised in the package insert.

The following language should be added to the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section (revised language is underlined):

Toxic epidermal necrolysis (TEN), oculomucocutaneous syndrome (Stevens-Johnson syndrome), erythema multiforme:

Toxic epidermal necrolysis, oculomucocutaneous syndrome, or erythema multiforme may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.

Pharmaceuticals and Medical Devices Agency